ClinicalTrials.gg
RecruitingNCT07856706Updated Oct 29, 2026

A Single Ascending Dose, and Food Effect Study of ABBV-7828 in Healthy Adults

A Phase 1 interventional study of ABBV-7828 and Placebo for ABBV-7828 in Healthy Subjects, sponsored by AbbVie. Recruiting at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-29.

Sponsored by AbbVie · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Started Oct 2026; still recruiting 1 month later.
Updated Oct 29, 2026Now RecruitingSite recruiting status changed+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This study is to evaluate safety, tolerability, pharmacokinetics and effect of food on ABBV-7828 compared to placebo in healthy adult participants.

02

Conditions studied

  • Healthy Subjects

Keywords

  • Healthy Adult Subjects
  • ABBV-7828
03

In context

Lead sponsor

AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.

Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Individuals between 18 to 65 years of age at the time of screening.
  • is \<= 18.0 to >= 32.0 kg/m2.
  • A condition of general good health, based upon the results of a medical history, physical evaluations, vital signs, laboratory profile and a 12-lead .

Exclusion criteria

Exclusion Criteria:

  • History of epilepsy, any cardiac, respiratory (except mild asthma as a child), renal, hepatic, gastrointestinal, hematologic or psychiatric disease or disorder, or any uncontrolled medical illness.
  • Has any clinically significant abnormalities including the following:

    • Evidence of 2nd or 3rd degree atrial ventricular (AV) block at screening visit or upon initial confinement
    • corrected for heart rate (QTc) using Fridericia's correction formula (QTcF) > 450 msec (males) or > 460 msec (females) at screening visit or upon initial confinement.
  • History of any clinically significant sensitivity or allergy to any medication or food.
  • History of or active medical condition(s) or surgical procedure(s) that might affect gastrointestinal motility, pH, or absorption.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Part 1: ABBV-7828

    Participants will receive single doses of ABBV-7828.

    Drug: ABBV-7828

  • Placebo comparator
    Part 1: Placebo

    Participants will receive single doses of placebo.

    Drug: Placebo for ABBV-7828

  • Experimental
    Part 2: ABBV-7828 Sequence 1

    Participants will receive ABBV-7828 while in fasting in Period 1 followed by ABBV-7828 after high fat/high calorie meal in Period 2.

    Drug: ABBV-7828

  • Experimental
    Part 2: ABBV-7828 Sequence 2

    Participants will receive ABBV-7828 after a high-fat/high calorie meal in Period 1 followed by ABBV-7828 in fasting conditions in Period 2.

    Drug: ABBV-7828

Interventions

  • DrugABBV-7828

    Oral administration

  • DrugPlacebo for ABBV-7828

    Oral administration

06

What researchers measure

Primary outcomes

  1. Number of Participants with Adverse Events (AEs)

    An adverse event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study.

    Time frame: Up to approximately 38 days

  2. Maximum Observed Serum Concentration (Cmax) of ABBV-7828

    Cmax of ABBV-7828

    Time frame: Up to approximately 10 days

  3. Time to Cmax (Tmax) of ABBV-7828

    Time to Cmax (Tmax) of ABBV-7828

    Time frame: Up to approximately 10 days

  4. Terminal Phase Elimination Rate Constant (Beta) of ABBV-7828

    Beta of ABBV-7828

    Time frame: Up to approximately 10 days

  5. Area Under the Plasma Concentration-Time Curve (AUC) From Time 0 to the Time of the Last Measurable Concentration (AUCt) of ABBV-7878

    AUCt of ABBV-7878

    Time frame: Up to approximately 10 days

  6. AUC From Time 0 to the Time Infinity (AUCinf) of ABBV-7878

    AUCinf of ABBV-7878

    Time frame: Up to approximately 10 days

07

Study locations

1 of 1 sites recruiting
  • Acpru /Id# 283545
    Grayslake, Illinois 60030, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Oct 2026 (actual). Primary completion is estimated for May 2027, 7 months after the start.

Start moved once since we started tracking on Sep 25, 2026: Sep 2026 → Oct 2026, on Oct 29, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 28, 2026
First posted
Oct 5, 2026
StartActual
Oct 2, 2026was Sep 2026
Primary completionEst.
May 2027
CompletionEst.
May 2027
Last update
Oct 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 29, 2026
Sites
Acpru /Id# 283545 is now Recruiting
Oct 29, 2026
Start date
Sep 21, 2026→Oct 2, 2026 (actual)
Oct 29, 2026
Registered
First appeared on the registry
Oct 5, 2026
Show all 2 updates
  1. Oct 29, 2026
    Not yet recruiting→Recruiting
    Acpru /Id# 283545 is now Recruiting
    Start date Sep 21, 2026→Oct 2, 2026 (now actual)
    + 1 other change: verification date
  2. Oct 5, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07856706
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Oct 5, 2026
Start date
Oct 2, 2026
Primary completion
May 2027 (estimated)
Completion
May 2027 (estimated)
Last update
Oct 29, 2026

Study contacts

ABBVIE CALL CENTER
Contact
abbvieclinicaltrials@abbvie.com
844-663-3742
ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion